Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2019 | Single agent ibrutinib produces long-term disease control in Waldenström’s: the pivotal trial

Steven Treon • 20 Jun 2019
ICML 2019
B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Rare Diseases Waldenström’s Macroglobulinemia Ibrutinib

Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, presents the final report of the pivotal trial of ibrutinib monotherapy for previously treated Waldenström’s macroglobulinemia (NCT01614821). This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Steven Treon

1:59
Updates in the response criteria for Waldenström’s macroglobulinemia
Steven Treon • 29 Sep 2023
2:23
Practical considerations when treating patients with WM: exciting agents & combinations
Steven Treon • 29 Sep 2023
1:54
Selecting the correct BTK inhibitor for patients with WM: lessons learned from the ASPEN trial
Steven Treon • 29 Sep 2023
1:47
Exciting updates in Waldenström’s macroglobulinemia: the value of BTK inhibitors
Steven Treon • 29 Sep 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals